+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Company Analysis: Ionis Pharmaceuticals

  • Company Profile
  • 44 Pages
  • January 2021
  • Pharma Intelligence
  • ID: 5357328
The publisher explores Ionis Pharmaceuticals’ prescription pharmaceutical performance and outlook over 2019-29.

Snapshot

  • Overview - Ionis’s prescription pharmaceutical business will see strong growth over the forecast period.
  • Key themes - [1] Spinraza royalties will comprise the majority of Ionis’s revenues for the foreseeable future [2] Pharmaceutical business growth driven by launches of Tegsedi and Waylivra.

Model updates (4 November 2020)

  • Tegsedi forecast adjusted lower

Model updates (5 August 2020)

  • Tegsedi forecast adjusted lower due to sales trends
  • Waylivra forecast adjusted lower due to sales trends
  • Other revenue adjusted lower due to lower upfront licensing fees.

Model updates (6 May 2020)

  • No changes to forecast.

Model updates (26 February 2020)

  • Waylivra forecast adjusted lower due to slower-than-anticipated launch.

Company Background
  • Company Overview
  • Key Metrics
  • SWOT Analysis
  • Key Drug & Company Information
  • Company Comparison

Recent Earnings Review
  • Earnings Overview

Company Forecast
  • Prescription Pharmaceuticals Sales Outlook
  • Branded Drug Outlook
  • Therapy Area Outlook
  • Regional Sales Outlook
  • Lifecycle Analysis

Company Profile
  • Marketed & Pipeline Drugs
  • Recent Events & Analyst Opinions
  • Upcoming Catalysts
  • Recent Insights

Clinical Trial Overview
  • Clinical Trial Snapshot
  • Clinical Trials by Country
  • Clinical Trials by Status and Phase
  • Clinical Trials by Drug